Ahead of her session on “Manufacturing Excellence” at CPHI Frankfurt (1–3 November), Elisabeth Stampa, President of Medicines for Europe, along with Adrian van den Hoven, Director General of Medicines for Europe, map out the impact of EU supply chain regulation on pharma companies in an exclusive article for Manufacturing Chemist
Open
Inflation is at an all-time high, opening an opportunity for CDMOs to invest in potentially cheaper sustainable alternatives.
The generic drug industry lobby group Medicines for Europe on Tuesday sent an open letter to European Union member states’ energy and health ministers.
“Digitalisation the key to efficient EU pharmaceutical regulation and easing of localised drug shortages”
Current EU regulatory systems too overwhelmed by paper, head of European association representing generics, biosimilars and value added medicines industries tells CPhI Worldwide online conference
Digitalisation is needed to update inefficient and paper-based European pharmaceutical regulatory systems as well as help ease localised medicines shortages in European Union member states, according to Adrian van den Hoven, Director General, Medicines for Europe in a keynote address at the CPhI Worldwide online conference Monday.